PMC:7195088 / 34333-34650
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1022 | 211-219 | Species | denotes | patients | Tax:9606 |
| 1023 | 275-286 | Chemical | denotes | ruxolitinib | MESH:C540383 |
| 1024 | 288-299 | Chemical | denotes | baricitinib | MESH:C000596027 |
| 1025 | 304-315 | Chemical | denotes | tofacitinib | MESH:C479163 |
| 1026 | 71-79 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1027 | 225-233 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T176 | 71-79 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T177 | 225-233 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T191 | 4-9 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T468 | 4-9 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
| T469 | 10-15 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T470 | 183-188 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T471 | 264-274 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
| T472 | 275-286 | Chemical | denotes | ruxolitinib | http://purl.obolibrary.org/obo/CHEBI_66919 |
| T473 | 304-315 | Chemical | denotes | tofacitinib | http://purl.obolibrary.org/obo/CHEBI_71200 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T277 | 0-133 | Sentence | denotes | Off-label drugs mostly provided in Italy during the first phase of the COVID-19 pandemic according to the authors' direct experience. |
| T278 | 134-317 | Sentence | denotes | Of note, there are also registered RCT for other drugs to be investigated in patients with COVID-19 (e.g. the Janus kinase family inhibitors ruxolitinib, baricitinib and tofacitinib). |